Seer Wins European Patent, ITC Investigates Nanomics
Analysis based on 6 articles · First reported Jul 01, 2026 · Last updated Jul 01, 2026
The market impact is positive for Seer, Inc. as the validation of its intellectual property strengthens its competitive position in the proteomics market. Conversely, Nanomics Biotechnology Company faces potential negative consequences, including a possible ban on its products in the United States, which could affect its market share and revenue.
Seer, Inc. announced two significant developments reinforcing its intellectual property portfolio. The International — European Patent Office upheld European Patent No. EP4056263, which covers Seer, Inc.'s particle-based enrichment technology for proteomics. Additionally, the United States — United States International Trade Commission initiated an investigation into Nanomics Biotechnology Company for allegedly infringing five of Seer, Inc.'s U.S. patents with its Proteonano kits and workstations. Seer, Inc. is seeking a limited exclusion order to prevent the importation and sale of Nanomics Biotechnology Company's products in the United States. Brigham and Women s Hospital, owner of the European patent and licensor to Seer, Inc., has joined the ITC action as a co-complainant. These actions follow a previous decision by the United States — United States Patent and Trademark Office's Patent Trial and Appeal Board upholding key claims of another U.S. Patent for Seer, Inc.. Omid Farokhzad, CEO of Seer, Inc., emphasized the company's commitment to defending its innovations.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard